Keywords: |
cancer chemotherapy; cancer survival; treatment response; clinical trial; cisplatin; doxorubicin; dose response; drug withdrawal; monotherapy; side effect; treatment planning; note; adjuvant therapy; chemotherapy, adjuvant; methotrexate; antineoplastic agent; metastasis; controlled clinical trial; multiple cycle treatment; kidney disease; mucosa inflammation; randomized controlled trial; antineoplastic combined chemotherapy protocols; peripheral neuropathy; editorial; combination chemotherapy; cyclophosphamide; dose-response relationship, drug; bladder cancer; cancer therapy; bladder tumor; urinary bladder neoplasms; vinblastine; febrile neutropenia; death; adjuvant chemotherapy; cystectomy; clinical research; epirubicin; drug substitution; transitional cell carcinoma; hearing loss; m vec protocol; m-vec protocol
|